Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences introduces a novel ferritin-based delivery system for small interfering RNA (siRNA) targeting ...

Details of each trial can be found on www.clinicaltrials.gov. † Ongoing trials. AMD: Age-related macular degeneration; DME: Diabetic macular edema; iv.: Intravenous ...

As a leading global provider of end-to-end clinical trial services, Novotech partners with biotech and pharmaceutical innovators to accelerate the development of siRNA therapeutics. Unlocking the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration ...

Researchers from Eli Lilly & Co. reported preclinical data on LY-3954068, a MAPT small-interference RNA (siRNA) strategy in AD models. The therapy is designed to reduce tau protein synthesis by ...

China NMPA approves Rona Therapeutics’ IND application for RN1871, a novel AGT-targeting siRNA drug for hypertension: Shanghai, China Tuesday, April 22, 2025, 18:00 Hrs [IST] Ro ...

By leveraging siRNA technology to treat disease fundamentally, RN1871 achieves sustained efficacy with less dosing frequency. We look forward to bringing this innovative therapy to hypertension ...